Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
The purpose of the Worta McCaskill-Stevens K12 funding opportunity is to support institutional career development awards designed to prepare newly trained clinicians who have made a commitment to independent research careers in community oncology or cancer prevention, and to facilitate their transition to more advanced support mechanisms or independent research funding (e.g., K08, R03, R21, R01).The NOFO will allow the appointment of Scholars proposing to serve as the lead investigator of an independent community-based clinical trial; or proposing a separate ancillary study to an existing prevention, screening or control clinical trial; or proposing to gain research experience in a community-based clinical trial led by another investigator; or proposing to serve as leader of innovative clinical trial approaches that expand engagement of a wide variety of communities in cancer clinical research, as part of their research and career development.
Funding Opportunity Number: PAR-24-153. Assistance Listing: 93.398,93.399. Funding Instrument: G. Category: ED,HL.
Based on current listing details, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is February 18, 2027. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active U19 awards funded under RFA-RM-22-015 as part ofthe NIH Somatic Cell Genome Editing program, in order to expand the scope of the original award to allow first in human genome editing clinical trials using the therapeutic clinical candidates developed through the U19 award. RFA-RM-22-015 did not allow a clinical trial, whereas the present NOFO (RFA-RM-24-008) requires a clinical trial. Funding Opportunity Number: RFA-RM-24-008. Assistance Listing: 93.310. Funding Instrument: CA. Category: HL.
To support secondary analysis of AnVIL datasets and increase utilization of the AnVIL platform for small research projects by eliminating the cost barriers new users face. Through this additional analysis, this RFA will illuminate the value of NHGRI datasets for secondary research and the effectiveness of AnVIL to stimulate further discovery. Funding Opportunity Number: RFA-HG-25-005. Assistance Listing: 93.172. Funding Instrument: G. Category: HL. Award Amount: Up to $125K per award.
The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. Funding Opportunity Number: PAR-25-209. Assistance Listing: 93.866. Funding Instrument: CA. Category: HL.
